Antibiotic use is associated with SJ syndrome and toxic epidermal necrosis, with sulfonamides being the most common culprits.

Published Date: 17 Feb 2023

Antibiotic use linked to SJ syndrome and toxic epidermal necrosis, sulfonamides are worst culprits in new study...

Read Full News

Latest News

Make the Diagnosis: This Cyst Is Asymptomatic. Is It a Problem?

A 67-year-old man visited the doctor for a cyst-like lesion that developed on his face 3 months prior.

Targeted Oral Drug Plus UV Therapy May Help in Extensive Vitiligo

Positive signs in phase II test

Novel Drug Eases Disease Activity in Dermatomyositis

Dazukibart targets specific molecular pathology of chronic systemic autoimmune disease

Biomarker May Flag Humira Responders in Hidradenitis Suppurativa

Patients' C-reactive protein levels also reflect significantly higher BMI and disease severity

What Botox Teaches Us About Serendipity in Clinical Encounters

Don't forget the power of a strong doctor-patient relationship

Make the Diagnosis: Are Her Nail Symptoms Part of a Larger Picture?

A 62-year-old woman visited her doctor about thick, crumbling, discolored toenails that developed over many months. Can you diagnose the patient?

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Latest News

A 67-year-old man visited the doctor for a cyst-like lesion that developed on his face 3 months prior.

Positive signs in phase II test

Dazukibart targets specific molecular pathology of chronic systemic autoimmune disease

Patients' C-reactive protein levels also reflect significantly higher BMI and disease severity

Don't forget the power of a strong doctor-patient relationship

A 62-year-old woman visited her doctor about thick, crumbling, discolored toenails that developed over many months. Can you diagnose the patient?

News All Time

Novel Drug for Chronic Inducible Urticaria Delivers in Mid-Stage Trial

Impressive responses with barzolvolimab in cold urticaria, symptomatic dermographism

Dupilumab Proves Effective in Chronic Spontaneous Urticaria

Significant reduction in hives and itch in antihistamine-resistant patients

50 Years After City Halted Prison Medical Testing, Families Seek Reparations

"No amount of money can replace what was done to me," said one former prisoner

Make the Diagnosis: She Feels Fine, But Why Do Her Fingers Look Like This?

A 38-year-old woman visited her doctor about itchy, raised spots that developed on her fingers 5 days prior. Can you diagnose the patient?

A Look at Kamala Harris' Medical History

Veep in "excellent health," doctor says, with history that includes seasonal allergies, urticaria

Selective Role for Single-Agent Ipilimumab After Anti-PD-1 Failure in Melanoma

Two-year survival in second line for patients with BRAF/NRAS wild-type tumors

Acne Treatments Taken Right Off the Shelf Had High Levels of Benzene

Study findings suggest cold storage may prevent breakdown into carcinogen

Make the Diagnosis: It’s Ugly, and It Hurts. What the Heck Is It?

A 29-year-old woman visited the doctor for a painful rash that developed on her arm 1 day after working on a landscaping project that involved pulling weeds under intense sunlight. Can you diagnose the patient?

Hitting Psoriatic Arthritis Early With Apremilast Helps Some Patients, Trial Finds

But only a minority achieved minimal disease activity within 16 weeks

Lebrikizumab Wins FDA Approval for Eczema

38% of patients treated with IL-13 blocker achieved clear or almost-clear skin at 16 weeks

Higher Steroid Dose for ICI Toxicity Harms Cancer Survival, Analysis Suggests

More data for discussion of controversial association between steroids, immunotherapy

Stopping JAK Inhibitor for Severe Alopecia Areata Led to Hair Loss

Long-term maintenance therapy is necessary, researchers caution

IL-31 Drug for Itchy Nodular Skin Disease Gets Thumbs Up From FDA

Nemolizumab significantly improved itch, nodules, and sleep disturbance at 16 weeks

IL-2 Receptor-Targeted Therapy Approved for Relapsed/Refractory CTCL

New iteration of denileukin diftitox led to objective responses in 36% of pretreated patients

Psoriasis Control Maintained Long Term With Extended Dosing Interval of Guselkumab

More than 90% of patients met response criteria at 68 weeks with 8- or 16-week dosing

Common Antibiotics Linked With Serious Skin Reactions in Older Adults

Sulfonamides and cephalosporins the worst offenders, study finds

Recommended News For You

Liver cancer survival rates reflect income disparities

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

Healthcare AI, Meant to Save Money, Turns Out to Require a Lot of Expensive Humans

Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models

A video animation guide to assist young people who are fatigued from cancer.

High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination

Getting More Done With Less Blood.

Recommended Articles For You

Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell 

Treating Methemoglobinemia: What You Need to Know Now! 

Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges 

A Clinical Review of Novel Therapeutics for Rare Cancers in the Genomics Era 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Ineffective medication can remove the "worst fear" of schizophrenia.

2.

GLP-1 receptor agonists, cancer risk and questionable significance

3.

Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US

4.

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

5.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

1.

Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications

2.

CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target

3.

Understanding QSOFA: A Vital Tool for Recognizing Sepsis 

4.

The Cutting-Edge of Phlebectomy: Redefining Vein Care

5.

Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

2.

Navigating the Complexities of Ph Negative ALL - Part XIV

3.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

4.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

5.

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot